TB drug susceptibility testing in high fluoroquinolone resistance settings.

ABSTRACT:

Background

The insurgence of resistance to key drugs of the BPaLM (bedaquiline + pretomanid + moxifloxacin) regimen is a major concern. In settings with widespread resistance to fluoroquinolones (FQs), like Pakistan, new technologies, such as Xpert^® MTB/XDR, may ensure drug resistance upfront screening. This study aims to assess MTB/XDR's performance in detecting FQs and isoniazid resistance, proposing a renewed diagnostic algorithm for drug-resistant TB (DR-TB).

Methods

This cross-sectional prospective study, approved by the local ethical committee, collected samples from people newly and previously diagnosed with TB over 6 months. Xpert^® MTB/RIF Ultra, MTB/XDR, Genotype^® MTBDRplus, Genotype^® MTBDRsl, culture, and ph

SUBMITTER: Saluzzo F 

PROVIDER: S-EPMC11249602 | biostudies-literature | 2024 May

REPOSITORIES: biostudies-literature